Abstract:Abstract A major immune dysregulation in lupus patients is the generation of autoantibodies targeting a range of self-molecules. Some of these lupus antibodies may have anti-tumor activity in high-grade glioma (HGG). An autoantibody, 3E10, was isolated from a mouse model of lupus that has high affinity for DNA. Two different humanized forms of 3E10 were generated, PAT-DX1 (a di-scFV) and PAT-DX3 (a humanized IgG1). Neither DX1 nor DX3 inhibited the in vitro growth of HGG patient-derived cell lines, either alone or in combination with radiotherapy (RT). In contrast, both antibody constructs inhibited the growth of GBM6 orthotopic xenografts in mice as single agents, consistent with our data showing uptake of labelled DX1 in HGG xenografts. Interestingly, despite its larger molecular weight, DX3 displayed greater anti-tumor activity than DX1, possibly due to improved tumor localization. DX1 showed at least additive anti-tumor activity in combination with RT against GBM6 xenografts, significantly extending survival. Neutrophils produce NETs, a proinflammatory form of cell death that generates web-like structures composed of various injurious enzymes and DNA. NET release promotes a favorable tumor environment through induction of cellular proliferation and angiogenesis. NETs cause resistance to therapeutics in a variety of cancers and their inhibition improves response to these therapeutics. Our published data shows that DX1 inhibits the formation of NETs in neutrophils, suggesting this could be its mechanism of action and is consistent with the lack of DX1 in vitro activity. Large scale production of DX1 has been optimized and toxicology and safety studies in rats and non-human primates have not identified any concerns. A first in human Phase 1 clinical trial of DX1 is planned in 2024 and will include HGG patients. Citation Format: Terrance G. Johns, Mani Kuchibhotla, Kim O'Sullivan, Zi Ying Ng, Ranjith Palanisamy, James Campbell, Valentina Dubljevic, Raelene Endersby. A novel lupus-associated antibody that inhibits the growth of aggressive high-grade glioma orthotopic xenografts and enhances radiotherapy via a unique mechanism [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr B029.

Abstract B029: A novel lupus-associated antibody that inhibits the growth of aggressive high-grade glioma orthotopic xenografts and enhances radiotherapy via a unique mechanism